GT Biopharma (GTBP) AI Stock Analysis

• Market Cap: $14.83M
• Dividend Yield: N/A
• Average Volume (3M): 1.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: N/A
• EPS Growth: 54.62%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 31,553,892
• 10 Day Avg. Volume: 1,818,785
• 30 Day Avg. Volume: 1,629,462
• PEG Ratio: 0.03
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.34
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $3.00
• Price Target Upside: 310.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.46 ▼(-37.53% Downside)
• Action: Upgraded Date: 03/02/26
• Date: Action: Upgraded 03/02/26

The score is primarily weighed down by weak financial performance—no revenue, large ongoing losses, and persistent cash burn that imply continued financing needs. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because a negative P/E reflects unprofitability and no dividend yield is provided.

Positive Factors

Regulatory/Clinical Milestone

FDA IND clearance for GTB-5550 advances a third TriKE candidate into clinical testing, broadening the company's biologics pipeline. Clinic entry materially de-risks that program, enables generation of human safety/early efficacy data, and validates the TriKE platform for solid tumor indications over the medium term.

Cash Runway

An estimated proforma cash balance of ~$9M gives GT Biopharma runway into Q4 2026, supporting initiation of the planned Phase 1 for GTB-5550 and continued GTB-3650 dosing. This funding window reduces immediate financing pressure and allows execution of near-term clinical milestones that are central to program advancement.

Low Leverage

A very low debt profile minimizes interest obligations and insolvency risk, preserving financial flexibility. For a clinical-stage biotech, low leverage allows the company to prioritize R&D spending and pursue equity, partnerships, or milestone-based financings without fixed repayment burdens that could constrain long-term project execution.

Negative Factors

Cash Burn

Sustained negative operating and free cash flow (~-$12.9M TTM) is a structural constraint for a pre-commercial biotech. With ongoing burn and no product revenue, GT Biopharma will remain dependent on external financing or partnerships to fund trials, creating recurring dilution risk and operational vulnerability if markets tighten.

No Revenue / Heavy Losses

The company is a pre-commercial R&D organization with no revenue and persistent heavy losses, which means long-term viability depends on successful clinical outcomes and future commercialization. Absent successful trials or partner support, the lack of revenue makes sustainable operations contingent on repeated financing rounds.

Eroding Equity Base

Material decline in shareholders' equity and a prior negative equity reading reflect cumulative operating losses that have eroded capital cushions. A weakened equity base reduces the company's ability to absorb trial setbacks and increases the likelihood of dilutive financings to restore balance-sheet strength, raising governance and solvency risk.

GT Biopharma Business Overview & Revenue Model

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

How the Company Makes Money

GT Biopharma makes money primarily through the development and commercialization of its proprietary TriKE platform, which is designed to create targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its product candidates upon regulatory approval. Key revenue streams include milestone payments, royalties on sales, and collaboration agreements with larger pharmaceutical companies. Additionally, GT Biopharma may receive funding from government grants and research collaborations to support its clinical trials and research initiatives.

GT Biopharma Financial Statement Overview

Summary

Financials reflect a pre-commercial biotech profile: no revenue, persistent heavy losses (TTM EBIT -$12.4M; net loss -$34.4M) and sustained cash burn (TTM operating/free cash flow about -$12.9M). Low leverage with essentially no debt reduces balance-sheet risk, but equity has been pressured over time and was negative in 2024, highlighting ongoing funding dependence until revenue materializes.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued heavy losses (EBIT of -$12.4M and net loss of -$34.4M). Losses have been persistent across years, with net income remaining negative in every annual period provided (e.g., -$13.2M in 2024 and -$7.6M in 2023), indicating the business has not yet demonstrated a repeatable earnings model. A positive is that operating loss levels have improved versus the very large 2021 loss, but profitability remains materially negative and volatile.

Balance Sheet

Leverage is very low with essentially no debt in TTM (Trailing-Twelve-Months) and 2024, which reduces financial risk. However, the equity base has been unstable—stockholders’ equity was negative in 2024 (-$1.7M) and has declined significantly from 2021 ($21.9M) to TTM (Trailing-Twelve-Months) ($5.8M). Returns on equity are highly negative in TTM (Trailing-Twelve-Months), reflecting that losses are eroding capital despite the light debt load.

Cash Flow

Cash generation remains weak with negative operating and free cash flow in every period shown, including TTM (Trailing-Twelve-Months) operating/free cash flow of about -$12.9M. Free cash flow improved modestly versus 2022, but it remains meaningfully negative and implies ongoing cash burn. With continued losses and cash outflows, funding needs likely remain elevated unless costs are reduced further or revenue ramps.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-34.32M	-13.16M	5.98M	-20.96M	-57.48M
Net Income	-34.45M	-13.16M	-7.60M	-20.88M	-58.01M
Balance Sheet
Total Assets	8.11M	4.23M	14.11M	16.74M	32.17M
Cash, Cash Equivalents and Short-Term Investments	6.81M	3.95M	13.97M	16.51M	31.98M
Total Debt	0.00	0.00	58.00K	174.00K	31.00K
Total Liabilities	2.32M	5.90M	6.63M	5.00M	10.26M
Stockholders Equity	5.79M	-1.67M	7.48M	11.73M	21.91M
Cash Flow
Free Cash Flow	-12.91M	-12.90M	-8.85M	-15.22M	-15.61M
Operating Cash Flow	-12.91M	-12.90M	-8.85M	-15.22M	-15.61M
Investing Cash Flow	0.00	12.89M	-2.01M	12.14M	-23.04M
Financing Cash Flow	15.78M	2.98M	6.27M	-224.00K	42.32M

GT Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.64, and below the 200-day MA of 1.28, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.14 is Neutral, neither overbought nor oversold. The STOCH value of 45.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.

GT Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$3.29M	-0.06	-203.36%	―	―	90.53%
TOVX	45 Neutral	$6.77M	-0.03	-166.96%	―	―	83.25%
REVB	42 Neutral	$4.58M	-0.02	-118.88%	―	―	96.26%
GTBP	41 Neutral	$14.83M	-0.08	-356.99%	―	―	54.62%
AZTR	41 Neutral	$2.82M	-0.05	-215.04%	―	-100.00%	93.82%